Greenwich LifeSciences Inc is a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variet... Greenwich LifeSciences Inc is a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in most breast cancers at low, intermediate, and high or overexpressor levels. Show more
STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical...
STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.34 | -8.93333333333 | 15 | 15.34 | 13.61 | 36970 | 14.1819603 | CS |
4 | 0.23 | 1.71258376768 | 13.43 | 16.5 | 13.1339 | 43277 | 14.48501248 | CS |
12 | -2.36 | -14.7315855181 | 16.02 | 17 | 12.75 | 34259 | 14.64949033 | CS |
26 | -4.12 | -23.1721034871 | 17.78 | 18.7499 | 11.375 | 34274 | 14.81894124 | CS |
52 | 4.93 | 56.4719358534 | 8.73 | 21.44 | 7.58 | 32861 | 13.87364844 | CS |
156 | -24.52 | -64.2221058146 | 38.18 | 40.25 | 6.8241 | 62442 | 13.5404519 | CS |
260 | 8.66 | 173.2 | 5 | 128 | 3.262 | 131089 | 33.45874381 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.